Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07662954

Effects of Magnesium and Spinning Training on Echocardiographic, Inflammatory, and Aerobic Outcomes

Regular aerobic exercise may improve cardiorespiratory fitness while modulating systemic inflammation and oxidative stress. Spinning, as a structured indoor cycling modality, provides a practical aerobic exercise model with adjustable intensity and duration, but its effects on redox balance, inflammatory status, aerobic capacity, and cardiac functional parameters may vary according to individual recovery and nutritional status. Magnesium is an essential micronutrient involved in energy metabolism, muscle contraction-relaxation, ion regulation, and inflammatory and oxidative pathways; therefore, magnesium use may be relevant to exercise adaptation and recovery.

This study aims to evaluate the associations of magnesium use and spinning training with oxidative stress, inflammation, aerobic capacity, and cardiac parameters. In this context, biochemical markers related to oxidative/antioxidant status and inflammation, aerobic performance indicators, and echocardiographic cardiac function parameters will be assessed together. The study is expected to provide real-world evidence on whether magnesium use in individuals participating in spinning training is associated with more favorable redox, inflammatory, aerobic, and cardiac profiles.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Oxidative Stress Behavior Echocardiography Exercise Healthy Volunteers Inflammation Motor Activity Pathologic Processes Pathological Conditions, Signs and Symptoms Physical Fitness

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Karamanoğlu Mehmetbey University, Faculty of Sport Sciences

Karaman, 70100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-identified male participants
  • Aged 18 to 30 years
  • Physically active individuals
  • Participants who are eligible to participate in a structured spinning training program
  • Participants with available baseline and follow-up assessments for biochemical, aerobic capacity, and cardiac function parameters

Exclusion criteria

  • Presence of any chronic systemic disease
  • Acute infection during the study period
  • Regular use of anti-inflammatory or antioxidant medications
  • Use of antioxidant or ergogenic supplements other than magnesium
  • Any cardiovascular, musculoskeletal, or neurological condition that may limit participation in spinning training
  • Missing baseline or follow-up outcome data

Treatment and study plan

Spinning Training

Behavioral

Participants will participate in a structured spinning training program during the study period. The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.

Magnesium Supplementation

Dietary Supplement

Participants will receive oral magnesium supplementation during the study period in addition to the structured spinning training program.

Primary outcomes

  1. Change in Maximal Oxygen Uptake (VO₂max)

    Time frame: Baseline and 6 weeks

    Maximal oxygen uptake (VO₂max, mL/kg/min) will be assessed using a graded exercise test. The change in VO₂max from baseline to 6 weeks will be evaluated.

  2. Change in Serum Magnesium Concentration

    Time frame: Baseline and 6 weeks

    Serum magnesium concentration (mg/dL) will be measured using standard laboratory methods. The change in serum magnesium levels from baseline to 6 weeks will be evaluated.

Secondary outcomes

  1. Change in Total Antioxidant Status (TAS)

    Time frame: Baseline and 6 weeks

    Serum total antioxidant status (TAS, mmol Trolox equivalent/L) will be measured using commercially available assay kits. The change in TAS from baseline to 6 weeks will be evaluated.

  2. Change in Total Oxidant Status (TOS)

    Time frame: Baseline and 6 weeks

    Serum total oxidant status (TOS, μmol H₂O₂ equivalent/L) will be measured using commercially available assay kits. The change in TOS from baseline to 6 weeks will be evaluated.

  3. Change in Paraoxonase-1 Activity (PON1)

    Time frame: Baseline and 6 weeks

    Serum paraoxonase-1 (PON1, U/L) activity will be determined using spectrophotometric methods. The change in PON1 activity from baseline to 6 weeks will be evaluated.

  4. Change in Arylesterase Activity (ARE)

    Time frame: Baseline and 6 weeks

    Serum arylesterase (ARE, kU/L) activity will be determined using spectrophotometric methods. The change in ARE activity from baseline to 6 weeks will be evaluated.

  5. Change in High-Sensitivity C-Reactive Protein (hs-CRP)

    Time frame: Baseline and 6 weeks

    Serum high-sensitivity C-reactive protein (hs-CRP, mg/L) concentration will be measured using standard laboratory methods. The change in hs-CRP levels from baseline to 6 weeks will be evaluated.

  6. Change in Interleukin-6 (IL-6)

    Time frame: Baseline and 6 weeks

    Serum interleukin-6 (IL-6, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in IL-6 levels from baseline to 6 weeks will be evaluated.

  7. Change in Tumor Necrosis Factor-Alpha (TNF-α)

    Time frame: Baseline and 6 weeks

    Serum tumor necrosis factor-alpha (TNF-α, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in TNF-α levels from baseline to 6 weeks will be evaluated.

  8. Change in Serum Potassium Concentration

    Time frame: Baseline and 6 weeks

    Serum potassium concentration (mmol/L) will be measured using standard biochemical methods. The change in serum potassium levels from baseline to 6 weeks will be evaluated.

  9. Change in Serum Calcium Concentration

    Time frame: Baseline and 6 weeks

    Serum calcium concentration (mg/dL) will be measured using standard biochemical methods. The change in serum calcium levels from baseline to 6 weeks will be evaluated.

  10. Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)

    Time frame: Baseline and 6 weeks

    Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) concentration will be measured using immunoassay methods. The change in NT-proBNP levels from baseline to 6 weeks will be evaluated.

  11. Change in Left Ventricular Ejection Fraction (LVEF)

    Time frame: Baseline and 6 weeks

    Left ventricular ejection fraction (LVEF, %) will be assessed by transthoracic echocardiography. The change in LVEF from baseline to 6 weeks will be evaluated.

Sponsors and collaborators

Lead sponsor

Karamanoğlu Mehmetbey University

Other

Registry information

Official study title

Effects of Magnesium Supplementation and Spinning Training on Cardiac Function, Oxidative Stress, Inflammation, and Aerobic Capacity

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 23, 2026
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.